GenoMed to be Awarded Second Patent, for Treating Acute Kidney Failure Without Dialysis
Contact: David Moskowitz MD GenoMed, Inc. tel. 314.983.9933
ST. LOUIS (June 14, 2005) - GenoMed, Inc.-- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol GMED), a St. Louis, Missouri-based biotechnology and Disease Management company, announced today that the US Patent Office has allowed claims and will be following up with an issued patent shortly on the Company's treatment to treat acute kidney failure with a drug rather than the dialysis machine.
Currently, patients with acute kidney failure are placed on the kidney machine in a hospital until their own kidney function improves. The older a person is, the less likely their kidneys are to recover, and the longer they have to stay on kidney dialysis. Acute kidney failure carries a 50% risk of dying, and involves a much longer and more expensive hospitalization.
GenoMed's treatment makes use of an already existing, generic drug. It has been used in adults, including those with hepatorenal syndrome, and newborns, with over a 70% success rate. A larger trial, for publication, is being planned.
GenoMed's treatment is ideal where access to kidney dialysis is scarce, e.g. after an earthquake, or on the battlefield, or in the Third World. First World countries interested in cutting healthcare costs and improving the atrocious mortality of acute renal failure might also be interested in the company's approach.
About GenoMed
GenoMed is a Next Generation DM™ company that translates knowledge of disease pathways into better patient outcomes so as to lower healthcare costs. GenoMed is currently marketing its patent-pending protocols for preventing chronic kidney failure due to high blood pressure or diabetes, and slowing down emphysema. The Company has recently developed a Healthchip® to predict the six most common cancers in Caucasians: breast, colon, lung, ovarian, pancreatic, and prostate. Testing is available on a research basis.
|
